Therefore, we first used Co-IP analyses to evaluate the interaction between MGMT and BRCA2 in NPC cells, which revealed an increase in the amount of BRCA2 conjugated with anti-MGMT antibodies in NPC cells treated with CDDP compared with control cells (Additional file 1: Fig. S2). This evidence concerns the gene MGMT and nasopharyngeal carcinoma.